Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer

被引:0
|
作者
Silvia Cantara
Eugenio Bertelli
Rossella Occhini
Marì Regoli
Lucia Brilli
Furio Pacini
Maria Grazia Castagna
Paolo Toti
机构
[1] University of Siena,Department of Medical, Surgical and Neurological Sciences
[2] University of Siena,Department of Molecular and Developmental Medicine
[3] Arezzo Hospital,Unit of Pathology
[4] University of Siena,undefined
来源
Endocrine | 2019年 / 64卷
关键词
PD-L1; PD-1; Anaplastic thyroid cancer; Immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:122 / 129
页数:7
相关论文
共 50 条
  • [31] Pan-cancer analysis of programmed death-ligand 1 (PD-L1) amplifications
    Budczies, Jan
    Bockmayr, Michael
    Klauschen, Frederick
    Weichert, Wilko
    Denkert, Carsten
    Stenzinger, Albrecht
    CANCER RESEARCH, 2016, 76
  • [32] Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer
    He, Peng-xing
    Ma, Zhi-lu
    Han, Huan
    Zhang, Xu-yang
    Niu, Sheng-hui
    Du, Lin-na
    Zheng, Yi-chao
    Liu, Hong-min
    LIFE SCIENCES, 2020, 242
  • [33] Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types
    Scognamiglio, Giosue
    De Chiara, Anna
    Di Bonito, Maurizio
    Tatangelo, Fabiana
    Losito, Nunzia Simona
    Anniciello, Annamaria
    De Cecio, Rossella
    D'Alterio, Crescenzo
    Scala, Stefania
    Cantile, Monica
    Botti, Gerardo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (05)
  • [34] Different expression of programmed death 1 (PD1) and its ligand (PD-L1) in esophageal and gastric cancer
    Daster, Silvio
    Eppenberger-Castori, Serenella
    Droeser, Raoul A.
    Schaefer, Hannah M.
    Spagnoli, Giulio C.
    Terracciano, Luigi
    Tornillo, Luigi
    von Holzen, Urs
    CANCER RESEARCH, 2016, 76
  • [35] Analysis of Expression of Programmed Cell Death Ligand 1 (PD-L1) and BRAFV600E Mutation in Thyroid Cancer
    Sekino, Mizuki
    Iwadate, Manabu
    Yamaya, Yukie
    Matsumoto, Yoshiko
    Suzuki, Satoshi
    Mizunuma, Hiroshi
    Nakano, Keiichi
    Nakamura, Izumi
    Suzuki, Shinichi
    CANCERS, 2023, 15 (13)
  • [36] Programmed death ligand 1 (PD-L1), Immune-Checkpoint Blockade with Combination Therapy in Syngeneic Colon Carcinoma Model.
    Ka, W. H.
    MOLECULAR BIOLOGY OF THE CELL, 2017, 28
  • [37] Fragment-based screening of programmed death ligand 1 (PD-L1)
    Perry, Evan
    Mills, Jonathan J.
    Zhao, Bin
    Wang, Feng
    Sun, Qi
    Christov, Plamen P.
    Tarr, James C.
    Rietz, Tyson A.
    Olejniczak, Edward T.
    Lee, Taekyu
    Fesik, Stephen
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (06) : 786 - 790
  • [38] Programmed death-ligand 1 (PD-L1) expression in pheochromocytoma.
    Hashimoto, Yasuhiro
    Yamamoto, Hayato
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [39] Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms
    Giunchi, Francesca
    Gevaert, Thomas
    Scarpelli, Marina
    Fiorentino, Michelangelo
    CURRENT DRUG TARGETS, 2020, 21 (13) : 1286 - 1292
  • [40] Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art
    Zanelli, Magda
    Fragliasso, Valentina
    Parente, Paola
    Bisagni, Alessandra
    Sanguedolce, Francesca
    Zizzo, Maurizio
    Broggi, Giuseppe
    Ricci, Stefano
    Palicelli, Andrea
    Foroni, Moira
    Gozzi, Fabrizio
    Gentile, Pietro
    Morini, Andrea
    Koufopoulos, Nektarios
    Caltabiano, Rosario
    Cimino, Luca
    Fabozzi, Massimiliano
    Cavazza, Alberto
    Neri, Antonino
    Ascani, Stefano
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)